BACKGROUND AND AIMS: Anandamide is an endocannabinoid that evokes hypotension by interaction with peripheral cannabinoid CB1 receptors and with the perivascular transient receptor potential vanilloid type 1 protein (TRPV1). As anandamide has been implicated in the vasodilated state in advanced cirrhosis, the study investigated whether the mesenteric bed from cirrhotic rats has an altered and selective vasodilator response to anandamide. METHODS: We assessed vascular sensitivity to anandamide, mRNA and protein expression of cannabinoid CB1 receptor and TRPV1 receptor, and the topographical distribution of cannabinoid CB1 receptors in resistance mesenteric arteries of cirrhotic and control rats. RESULTS: Mesenteric vessels of cirrhotic animals displayed greater sensitivity to anandamide than control vessels. This vasodilator response was reverted by CB1 or TRPV1 receptor blockade, but not after endothelium denudation or nitric oxide inhibition. Anandamide had no effect on distal femoral arteries. CB1 and TRPV1 receptor protein was higher in cirrhotic than in control vessels. Neither CB1 mRNA nor protein was detected in femoral arteries. Immunochemistry showed that CB1 receptors were mainly in the adventitia and in the endothelial monolayer, with higher expression observed in vessels of cirrhotic rats than in controls. CONCLUSIONS: These results indicate that anandamide is a selective splanchnic vasodilator in cirrhosis which predominantly acts via interaction with two different types of receptors, CB1 and TRPV1 receptors, which are mainly located in perivascular sensory nerve terminals of the mesenteric resistance arteries of these animals.
BACKGROUND AND AIMS: Anandamide is an endocannabinoid that evokes hypotension by interaction with peripheral cannabinoid CB1 receptors and with the perivascular transient receptor potential vanilloid type 1 protein (TRPV1). As anandamide has been implicated in the vasodilated state in advanced cirrhosis, the study investigated whether the mesenteric bed from cirrhotic rats has an altered and selective vasodilator response to anandamide. METHODS: We assessed vascular sensitivity to anandamide, mRNA and protein expression of cannabinoid CB1 receptor and TRPV1 receptor, and the topographical distribution of cannabinoid CB1 receptors in resistance mesenteric arteries of cirrhotic and control rats. RESULTS: Mesenteric vessels of cirrhotic animals displayed greater sensitivity to anandamide than control vessels. This vasodilator response was reverted by CB1 or TRPV1 receptor blockade, but not after endothelium denudation or nitric oxide inhibition. Anandamide had no effect on distal femoral arteries. CB1 and TRPV1 receptor protein was higher in cirrhotic than in control vessels. Neither CB1 mRNA nor protein was detected in femoral arteries. Immunochemistry showed that CB1 receptors were mainly in the adventitia and in the endothelial monolayer, with higher expression observed in vessels of cirrhotic rats than in controls. CONCLUSIONS: These results indicate that anandamide is a selective splanchnic vasodilator in cirrhosis which predominantly acts via interaction with two different types of receptors, CB1 and TRPV1 receptors, which are mainly located in perivascular sensory nerve terminals of the mesenteric resistance arteries of these animals.
Authors: S Bátkai; Z Járai; J A Wagner; S K Goparaju; K Varga; J Liu; L Wang; F Mirshahi; A D Khanolkar; A Makriyannis; R Urbaschek; N Garcia; A J Sanyal; G Kunos Journal: Nat Med Date: 2001-07 Impact factor: 53.440
Authors: S J Wigg; M Tare; M A Tonta; R C O'Brien; I T Meredith; H C Parkington Journal: Am J Physiol Heart Circ Physiol Date: 2001-07 Impact factor: 4.733
Authors: P M Zygmunt; J Petersson; D A Andersson; H Chuang; M Sørgård; V Di Marzo; D Julius; E D Högestätt Journal: Nature Date: 1999-07-29 Impact factor: 49.962
Authors: Vincenzo Di Marzo; L De Petrocellis; F Fezza; A Ligresti; T Bisogno Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2002 Feb-Mar Impact factor: 4.006
Authors: M Ghasemi; H Sadeghipour; H Shafaroodi; B G Nezami; T Gholipour; A R Hajrasouliha; S Tavakoli; M Nobakht; K P Moore; A R Mani; A R Dehpour Journal: Br J Pharmacol Date: 2007-05-08 Impact factor: 8.739
Authors: Javier Muñoz-Luque; Josefa Ros; Guillermo Fernández-Varo; Sònia Tugues; Manuel Morales-Ruiz; Carlos E Alvarez; Scott L Friedman; Vicente Arroyo; Wladimiro Jiménez Journal: J Pharmacol Exp Ther Date: 2007-11-20 Impact factor: 4.030